Sanofi-aventis (Value Right) (GCVRZ) - NASDAQ
  • Nov. 17, 2014, 7:19 AM
    • GCVRZ is up 135% to $1.20 in early premarket action after the FDA approved Lemtrada late on Friday. The deadline for a $1 payment with FDA approval has passed, so the next milestone would be for $2 if the drug exceeds $400M in worldwide sales over a four-quarter period.
    • The question: Is GCVRZ a better buy at $1.20 with approval in hand than at $0.50 without yet having approval?
    • GCVRZ forum
    • Previously: Genzyme's Lemtrada approved by the FDA
    • SNY -0.2% premarket
    | Nov. 17, 2014, 7:19 AM | 16 Comments
  • Nov. 14, 2014, 9:47 PM
    • Lemtrada was originally rejected by the FDA at the end of last year, but the Sanofi (NYSE:SNY) subsidiary resubmitted the application several months ago. With the FDA's action today, the U.S. joins pretty much the entirety of the rest of the globe in approving Lemtrada for treating relapsing forms of multiple sclerosis.
    • The contingent value rights on the drug (NASDAQ:GCVRZ) were trading at nearly $2 each before the FDA's rejection last year and closed today's session at $0.52. Monday should be interesting.
    • GCVRZ Forum
    | Nov. 14, 2014, 9:47 PM | 18 Comments
Company Description
Sanofi is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company also discovers, develops and distributes therapeutic solutions.
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: France